Loading…
Employees: 856
Size Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ) is a China Health Care company (Medical Specialties) with a market value of $750M, the 2907th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥108.52 on 6 Nov 2026.
Performance Over six months the shares gained 176.8%, against -10.0% for the median peer and -16.4% for the China market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue fell 14.0% over the last twelve months (peer median +14.8%); the operating margin is 3.2% (peer median 11.5%).
Valuation It trades at 11.1× enterprise value to sales against a peer median of 3.1× (2nd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.1 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥413M | CN¥457M | CN¥476M | CN¥533M | CN¥546M |
| Revenue growth | — | -4% | -11% | -2% | — |
| Gross profit | CN¥95.7M | CN¥61.4M | CN¥79.9M | CN¥109M | CN¥119M |
| EBITDA | n/a | CN¥54.3M | CN¥69.1M | CN¥86.6M | CN¥77.2M |
| Net income | CN¥17.9M | CN¥18.9M | CN¥40.0M | CN¥60.3M | CN¥70.9M |
| Free cash flow | CN¥14.4M | CN¥59.1M | CN¥53.7M | -CN¥18.9M | -CN¥53.0M |
| Capital expenditure | CN¥36.9M | CN¥19.8M | CN¥37.0M | CN¥70.9M | CN¥164M |
| Total debt | CN¥495,568 | CN¥680,413 | CN¥1.95M | CN¥782,956 | CN¥849,303 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301234.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.7% | -2.0% | lowest of 21 |
| 6-month return | +176.8% | -10.0% | highest of 21 |
| Distance from 52-week high | -31.1% | -24.9% | 10th lowest of 21 |
| Revenue growth (TTM) | -14.0% | +14.8% | lowest of 21 |
| Operating margin | 3.2% | 11.5% | 5th lowest of 21 |
| EV / Sales | 11.1× | 3.1× | 2nd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 33.5% | 0.1% | most demanding of 14 |
| Growth delivered (Del g) | -0.6% | +14.2% | lowest of 14 |
| Hurdle (Req g minus delivered) | +34.1 pp | -13.9 pp | most demanding of 14 |
| ROIC minus cost of capital | +4.1 pp | +0.3 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | 11.1× | 33.5% | -0.6% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 3.3× | 13.5% | +13.3% |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 3.3× | -2.4% | +15.7% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | 2.6× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 2.8× | -2.1% | +11.8% |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 0.7× | -10.5% | +12.4% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 1.4× | n/a | n/a |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 1.6× | 11.1% | +14.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 3.7× | 16.7% | +25.9% |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 2.0× | 0.1% | +15.6% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 1.2× | n/a | n/a |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 4.1× | -2.1% | +23.5% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 3.4× | 21.1% | +13.2% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 3.0× | 0.1% | +40.3% |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | 8.9× | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 0.9× | -8.0% | +6.6% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | 1.6× | n/a | n/a |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | 17.2× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | 7.6× | n/a | n/a |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 7.2× | 29.1% | +6.8% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 6.8× | 21.1% | +24.2% |